Technology
Health
Pharmaceutical
Verona Pharma
$6.149876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$6.14
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.00 (-0.01%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Verona Pharma and other stocks, options, ETFs, and crypto commission-free!
About
Verona Pharma plc American Depositary Share, also called Verona Pharma, is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Read More Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, United Kingdom.
Employees
12,000
Headquarters
London, London & South East
Founded
2005
Market Cap
80.85M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
8.44K
High Today
$6.14
Low Today
$6.14
Open Price
$6.14
Volume
108.00
52 Week High
$25.55
52 Week Low
$5.52
Collections
Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2017 IPO
UK
News
Markets InsiderMar 4
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
Single dose of ensifentrine DPI formulation produced statistically significant and clinically meaningful dose-dependent bronchodilator response and was well tolerated at all doses Data support initiation of part 2 of study to evaluate effect of ensifentrine DPI formulation over one week of treatment First study to show efficacy of DPI formulation; Delivery via DPI could dramatically expand the clinical utility and commercial opportunity for ensifentrine in COPD and asthma LONDON, March 04, 2019 (GL...
Guru FocusFeb 28
Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
LONDON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) ( VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces that the Company’s management team will present and conduct face-to-face meetings at the Cowen and Company 39th Annual Health Care Conference. Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present on Wednesday, March 13th at 10:00 am ET. A webca...
Markets InsiderFeb 20
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
LONDON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will report its audited financial results for the full year ended December 31, 2018 on Tuesday, February 26, 2019. Verona Pharma will host an investment community conference call at 8:00 a.m. Eastern Standard Time (2:00 p.m. Greenwich Mean Time) on Tuesd...
Price Paid on Robinhood
29% Lower
Right Now
52 Week Low
$5.52
Average Price Paid
$8.63
52 Week High
$25.55
Earnings
-$0.93
-$0.62
-$0.30
$0.01
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, Pre-Market